Not all acute coronary syndrome patients get appropriate tx

February 26, 2014
Not all acute coronary syndrome patients get appropriate tx
Nearly one in five eligible patients hospitalized for acute coronary syndrome do not receive American College of Cardiology/American Heart Association class I guideline-recommended angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, according to a study published online Feb. 25 in Circulation: Cardiovascular Quality and Outcomes.

(HealthDay)—Nearly one in five eligible patients hospitalized for acute coronary syndrome do not receive American College of Cardiology/American Heart Association (ACC/AHA) class I guideline-recommended angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, according to a study published online Feb. 25 in Circulation: Cardiovascular Quality and Outcomes.

Kevin R. Bainey, M.D., from the University of Alberta in Edmonton, Canada, and colleagues examined the extent to which ACEI/ARB therapy is applied in patients with . Data were collected from 80,241 patients admitted with an acute coronary syndrome and discharged home from 311 U.S. hospitals participating in the Get With the Guidelines-Coronary Artery Disease Program (January 2005 to December 2009).

The researchers found that 81 percent of the 60,847 patients with an ACC/AHA class I indication (left ventricular dysfunction or medical history of heart failure, hypertension, diabetes mellitus, or ) received ACEI/ARB. The rate of treatment increased over the study period (76.7 to 84.6 percent; adjusted odds ratio [OR], 1.17; P < 0.001, per calendar year). There were independent associations between in-hospital coronary bypass grafting (adjusted OR, 0.55) and renal insufficiency (adjusted OR, 0.58) with lower usage.

"These findings highlight an unmet need in this population and provide an incentive for additional quality improvement efforts," the authors write.

The Get With the Guidelines-Coronary Artery Disease Program is supported in part by Merck/Schering-Plough and Pfizer. Several authors disclosed financial ties to the medical device and pharmaceutical industries.

Explore further: Antihypertensives associated with lower dialysis risk for patients with advanced CKD

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Anatomic, not ischemic, burden predicts poor outcomes in CAD

January 20, 2014

(HealthDay)—For patients with coronary artery disease treated with optimal medical therapy (OMT), anatomic, but not ischemic, burden predicts poor outcomes, according to a study published online Jan. 15 in the Journal of ...

Clinical outcomes similar for elderly with PCI, CABG

August 27, 2013

(HealthDay)—For older patients with unprotected left main coronary artery disease, clinical outcomes are similar with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), according to research ...

Low risk with normal coronary arteries, nonobstructive CAD

April 5, 2013

(HealthDay)—Patients who experience acute chest pain, and have nonobstructive coronary artery disease (CAD), as determined by coronary computed tomographic angiography, have similarly benign outcomes as those with normal ...

Recommended for you

Optimism may reduce risk of dying prematurely among women

December 7, 2016

Having an optimistic outlook on life—a general expectation that good things will happen—may help people live longer, according to a new study from Harvard T.H. Chan School of Public Health. The study found that women ...

New discovery at heart of healthy cereals

December 6, 2016

A new discovery at the University of Queensland could help reduce heart disease and boost nutrition security – the access to balanced nourishment - globally.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.